170 related articles for article (PubMed ID: 31529682)
21. Progression of joint damage in early rheumatoid arthritis: association with HLA-DRB1, rheumatoid factor, and anti-citrullinated protein antibodies in relation to different treatment strategies.
de Vries-Bouwstra JK; Goekoop-Ruiterman YP; Verpoort KN; Schreuder GM; Ewals JA; Terwiel JP; Ronday HK; Kerstens PJ; Toes RE; de Vries RR; Breedveld FC; Dijkmans BA; Huizinga TW; Allaart CF
Arthritis Rheum; 2008 May; 58(5):1293-8. PubMed ID: 18438829
[TBL] [Abstract][Full Text] [Related]
22. Outcome of patients with early arthritis without rheumatoid factor and ACPA and predictors of rheumatoid arthritis in the ESPOIR cohort.
Mouterde G; Rincheval N; Lukas C; Daien C; Saraux A; Dieudé P; Morel J; Combe B
Arthritis Res Ther; 2019 Jun; 21(1):140. PubMed ID: 31171038
[TBL] [Abstract][Full Text] [Related]
23. Association of cumulative anti-cyclic citrullinated protein antibodies with radiographic progression in patients with rheumatoid arthritis.
Joo YB; Park YJ; Park KS; Kim KJ
Clin Rheumatol; 2019 Sep; 38(9):2423-2432. PubMed ID: 31049760
[TBL] [Abstract][Full Text] [Related]
24. Predictors of drug survival for biologic and targeted synthetic DMARDs in rheumatoid arthritis: Analysis from the TRA Clinical Electronic Registry.
Lin CT; Huang WN; Tsai WC; Chen JP; Hung WT; Hsieh TY; Chen HH; Hsieh CW; Lai KL; Tang KT; Tseng CW; Chen DY; Chen YH; Chen YM
PLoS One; 2021; 16(4):e0250877. PubMed ID: 33930048
[TBL] [Abstract][Full Text] [Related]
25. Cost-effective Tapering Algorithm in Patients with Rheumatoid Arthritis: Combination of Multibiomarker Disease Activity Score and Autoantibody Status.
Hagen M; Englbrecht M; Haschka J; Reiser M; Kleyer A; Hueber A; Manger B; Figueiredo C; Cobra JF; Tony HP; Finzel S; Kleinert S; Wendler J; Schuch F; Ronneberger M; Feuchtenberger M; Fleck M; Manger K; Ochs W; Lorenz HM; Nüsslein H; Alten R; Henes J; Krüger K; Schett G; Rech J
J Rheumatol; 2019 May; 46(5):460-466. PubMed ID: 30504510
[TBL] [Abstract][Full Text] [Related]
26. Potential benefits of biologics on stroke and mortality in patients with rheumatoid arthritis: A nationwide population-based cohort study in Taiwan.
Tang CH; Yu F; Huang CY; Chen DY
Int J Rheum Dis; 2019 Aug; 22(8):1544-1552. PubMed ID: 31240863
[TBL] [Abstract][Full Text] [Related]
27. Value of anti-modified citrullinated vimentin and third-generation anti-cyclic citrullinated peptide compared with second-generation anti-cyclic citrullinated peptide and rheumatoid factor in predicting disease outcome in undifferentiated arthritis and rheumatoid arthritis.
van der Linden MP; van der Woude D; Ioan-Facsinay A; Levarht EW; Stoeken-Rijsbergen G; Huizinga TW; Toes RE; van der Helm-van Mil AH
Arthritis Rheum; 2009 Aug; 60(8):2232-41. PubMed ID: 19644872
[TBL] [Abstract][Full Text] [Related]
28. Subcutaneous abatacept for the treatment of rheumatoid arthritis in routine clinical practice in Germany, Austria, and Switzerland: 2-year retention and efficacy by treatment line and serostatus.
Alten R; Tony HP; Bannert B; Nüßlein H; Rauch C; Connolly SE; Chartier M; Lozenski K; Hackl R; Forster A; Peichl P
Clin Rheumatol; 2023 Sep; 42(9):2321-2334. PubMed ID: 37314665
[TBL] [Abstract][Full Text] [Related]
29. Evaluating relationships between symptom duration and persistence of rheumatoid arthritis: does a window of opportunity exist? Results on the Leiden early arthritis clinic and ESPOIR cohorts.
van Nies JA; Tsonaka R; Gaujoux-Viala C; Fautrel B; van der Helm-van Mil AH
Ann Rheum Dis; 2015 May; 74(5):806-12. PubMed ID: 25561360
[TBL] [Abstract][Full Text] [Related]
30. Rheumatoid factor, not antibodies against citrullinated proteins, is associated with baseline disease activity in rheumatoid arthritis clinical trials.
Aletaha D; Alasti F; Smolen JS
Arthritis Res Ther; 2015 Aug; 17(1):229. PubMed ID: 26307354
[TBL] [Abstract][Full Text] [Related]
31. Predictors at diagnosis for start of biologic disease-modifying antirheumatic drugs in patients with early rheumatoid arthritis: a cohort study.
Hameed M; Exarchou S; Eberhard A; Sharma A; Bergström U; Cagnotto G; Einarsson JT; Turesson C
BMJ Open; 2024 Feb; 14(2):e076131. PubMed ID: 38382962
[TBL] [Abstract][Full Text] [Related]
32. Factors that influence biological survival in rheumatoid arthritis: results of a real-world academic cohort from the Netherlands.
van Mulligen E; Ahmed S; Weel AEAM; Hazes JMW; van der Helm-van Mil AHM; de Jong PHP
Clin Rheumatol; 2021 Jun; 40(6):2177-2183. PubMed ID: 33415451
[TBL] [Abstract][Full Text] [Related]
33. Autoantibody status is not associated with early treatment response to first-line methotrexate in patients with early rheumatoid arthritis.
Dekkers JS; Bergstra SA; Chopra A; Tikly M; Fonseca JE; Salomon-Escoto K; Huizinga TWJ; van der Woude D
Rheumatology (Oxford); 2019 Jan; 58(1):149-153. PubMed ID: 30204896
[TBL] [Abstract][Full Text] [Related]
34. Anticitrullinated protein antibodies and rheumatoid factor are associated with increased mortality but with different causes of death in patients with rheumatoid arthritis: a longitudinal study in three European cohorts.
Ajeganova S; Humphreys JH; Verheul MK; van Steenbergen HW; van Nies JA; Hafström I; Svensson B; Huizinga TW; Trouw LA; Verstappen SM; van der Helm-van Mil AH
Ann Rheum Dis; 2016 Nov; 75(11):1924-1932. PubMed ID: 26757747
[TBL] [Abstract][Full Text] [Related]
35. Presence of autoantibodies in "seronegative" rheumatoid arthritis associates with classical risk factors and high disease activity.
Reed E; Hedström AK; Hansson M; Mathsson-Alm L; Brynedal B; Saevarsdottir S; Cornillet M; Jakobsson PJ; Holmdahl R; Skriner K; Serre G; Alfredsson L; Rönnelid J; Lundberg K
Arthritis Res Ther; 2020 Jul; 22(1):170. PubMed ID: 32678001
[TBL] [Abstract][Full Text] [Related]
36. Incident Rheumatoid Arthritis in HIV Infection: Epidemiology and Treatment.
Hanberg JS; Hsieh E; Akgün KM; Weinstein E; Fraenkel L; Justice AC;
Arthritis Rheumatol; 2021 Dec; 73(12):2189-2199. PubMed ID: 34042306
[TBL] [Abstract][Full Text] [Related]
37. Factors associated with drug survival on first biologic therapy in patients with rheumatoid arthritis: a population-based cohort study.
Naffaa ME; Hassan F; Golan-Cohen A; Merzon E; Green I; Saab A; Paz Z
Rheumatol Int; 2021 Nov; 41(11):1905-1913. PubMed ID: 34529109
[TBL] [Abstract][Full Text] [Related]
38. The Clinical Impact of Seropositivity on Treatment Response in Patients with Rheumatoid Arthritis Treated with Etanercept: A Real-World Iraqi Experience.
Ridha A; Hussein S; AlJabban A; Gunay LM; Gorial FI; Al Ani NA
Open Access Rheumatol; 2022; 14():113-121. PubMed ID: 35756976
[TBL] [Abstract][Full Text] [Related]
39. Levels of anti-citrullinated protein antibodies and IgM rheumatoid factor are not associated with outcome in early arthritis patients: a cohort study.
Ursum J; Bos WH; van Dillen N; Dijkmans BA; van Schaardenburg D
Arthritis Res Ther; 2010; 12(1):R8. PubMed ID: 20064278
[TBL] [Abstract][Full Text] [Related]
40. Differential response of the rheumatoid factor and anticitrullinated protein antibodies during adalimumab treatment in patients with rheumatoid arthritis.
Bos WH; Bartelds GM; Wolbink GJ; de Koning MH; van de Stadt RJ; van Schaardenburg D; Dijkmans BA; Nurmohamed MT
J Rheumatol; 2008 Oct; 35(10):1972-7. PubMed ID: 18785316
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
